PIL against digital thermometer, BP monitor being notified as drugs: HC seeks Centre's stand

Image
Press Trust of India New Delhi
Last Updated : Sep 29 2019 | 2:55 PM IST

The Delhi High Court has sought the Centre's response on a plea challenging its decision to notify blood monitoring devices, digital thermometers, nebulizers and glucometers as 'drugs' under the Drugs and Cosmetics Act.

A bench of Chief Justice D N Patel and Justice C Hari Shankar issued a notice to the Health Ministry whose notification has been challenged by an association representing manufacturers and traders of surgical and other medical equipment.

The court asked the ministry to file its reply before the next date of hearing on December 11.

The association, in its PIL, has contended that none of the notified devices have a drug component and therefore, bringing them under the ambit of the Act was an arbitrary decision.

The petition, filed through advocates Harsh Kumar, Bhagya Yadav and Aditya Raj, claims that the notification would create an unwarranted burden of expenditure on importers, traders and manufacturers of these devices and consequently, it would be passed on to the consumers.

It said notifying the devices as drugs will result in a substantial hike in their prices which would make them unaffordable for a large segment of society.

Apart from seeking quashing of the notification, the association has also challenged the Constitutional validity of provisions of the Act.

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 29 2019 | 2:55 PM IST

Next Story